Hillevax Inc

Hillevax — Investor Presentation (January 2023)

22 slides from Hillevax's investor presentation, Jan 9, 2023

  1. Slide 1: Corporate presentation January 2023

    Corporate presentation January 2023 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    We caution you that this presentation contains forward-looking statements of HilleVax, Inc. (“HilleVax,” “we,” “us” or similar terms). All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financia

  3. Slide 3: Potential breakthrough for the prevention of norovirus-related illness

    Potential breakthrough for the prevention of norovirus-related illness Significant unmet medical need Potential to be first vaccine approved for norovirus-related illness 9 Phase I & II studies completed in >4,500 subjects Clinical PoC demonstrated in adult Phase IIb study Phase IIb clinical trial o

  4. Slide 4: Senior Leadership

    Senior Leadership Astrid Borkowski, MD, PhD CMO VP, Head of Clinical Development, Takeda Vaccines CMO, Europe, Novartis Vaccines Paul Bavier, JD GC & CAO GC, Velos Bio GC, Avedro GC, Biodel Rob Hershberg, MD, PhD CEO & Chair EVP BD & CSO, Celgene CEO, VentiRx CMO, Dendreon Anju Chatterji, PhD CTO SV

  5. Slide 5: Board of Directors

    Board of Directors Shelley Chu, MD, PhD Partner, Lightspeed Gary Dubin, MD President, Global Vaccine Business Unit, Takeda Julie Gerberding, MD, MPH President, Merck Vaccines Director, CDC Patrick Heron Managing General Partner, Frazier Rob Hershberg, MD, PhD, Chair Co-founder & CEO, HilleVax EVP BD

  6. Slide 6: Norovirus is the most common cause of acute gastroenteritis in US and worldwide

    Norovirus is the most common cause of acute gastroenteritis in US and worldwide1 1. Centers for Disease Control and Prevention website, 2021 2. Saito et al., 2014; Cannon et al., 2019 Key vulnerable populations Young children Endemic, incidence of norovirus highest among young children2 Adults Outbr

  7. Slide 7: Norovirus global annual burden is high

    1. Bartsch et al., 2016 2. Bartsch et al., 2020 Norovirus global annual burden is high… Direct Medical Clinical management, hospitalizations, infection control measures and cleaning, surveillance Indirect Health Productivity losses: sick staff work days, resources not used while managing outbreak Co

  8. Slide 8: Norovirus incidence by strain

    1. Inaida S et al., PLoS One 2013 2. Yu Y Biomed Res Int. 2014; 2014 (ID 196169): 1-13 3. Public Health England. PHE National norovirus and rotavirus report. 10 Jul 2014 4. Bernard H, et al. Epi infect 2014; 142(1): 63-74 Norovirus incidence by strain % total incidence GI and GII.4 genotypes compris

  9. Slide 9: HIL-214 comprises VLPs for major genotypes GI.1 and GII.4

    HIL-214 comprises VLPs for major genotypes GI.1 and GII.4 GI.1 selected based on its potential to promote a broad immune response to GI strains GII.4 selected because it is estimated to be responsible for nearly two-thirds of norovirus illness1 1 Virus-Like Particles (VLPs) Conformationally correct

  10. Slide 10: HIL-214 clinical studies overview

    1. Intranasal formulation of vaccine, not included in HIL-214 safety and immunogenicity subject numbers R: randomized. DB: double-blind. OL: open label. Pbo: placebo-controlled Trial No. Phase Design Study Population HIL-214 safety, n HIL-214 immuno, n LV01-103 I/II R, DB, Pbo, NoV challenge for saf

  11. Slide 11: HIL-214 clinical data have substantially de-risked the program

    We believe that HIL-214 clinical data have substantially de-risked the program Dose selection Adjuvant selection Immunogenicity in infants/children Immunogenicity in adults/older adults Efficacy proof-of-concept in adults Safety/tolerability profile 5-year safety and immunogenicity HIL-214 Key Clini

  12. Slide 12: Safety

    SAFETY >4,500 subjects (839 pediatric subjects) received vaccine in clinical studies In adults, local AEs all mild/moderate with systemic AEs similar to placebo Infant AEs largely mild to moderate with short duration (<3-4 days) HIL-214 clinical AE profile comparable to commercial vaccines Adult saf

  13. Slide 13: HIL-214 immunogenicity

    HIL-214 immunogenicity HBGA is an attachment factor on the surface of intestinal epithelia known to promote norovirus entry into host cells Measurement of HBGA-blocking antibodies is the primary method to assess vaccine immunogenicity against norovirus Data from long-term immunogenicity study in adu

  14. Slide 14: Phase 2b demonstrated reduction in moderate-to-severe AGE

    Cases of moderate-to-severe AGE Viral efficacy Pathogen Placebo n = 2,357 HIL-214 n = 2,355 % p value 1° HIL-214 vaccine strain only1 5 (0.2) 1 (<0.1) 80.0 p = 0.142 2° Any NoV strain 26 (1.1) 10 (0.4) 61.8 p = 0.0097 Post-hoc GII.2 strain 21 9 57.4 p = 0.0321 Phase 2b demonstrated reduction in mode

  15. Slide 15: Initial development focused primarily on the infant population

    We intend to focus our initial development primarily on the infant population Endemic pattern of infection Higher prevalence of GII.4 Comparison to subjects without pre-existing immunity Regulatory and operational precedent of rotavirus vaccines Advantages of studying HIL-214 in infants

  16. Slide 16: NEST-IN1 Phase 2b pediatric study ongoing

    NEST-IN1 Phase 2b pediatric study ongoing 1 Vaccinations at Day 1 and Day 29 - 57 2 Key secondary endpoints may include evaluation of efficacy against any GI or GII norovirus strain HIL-2141 (n = 1,500) Placebo1 (n = 1,500) Primary Endpoint Efficacy against moderate/ severe AGE due to HIL-214 vaccin

  17. Slide 17: NEST-IN1 has achieved significant milestones since 2Q22 initiation

    NEST-IN1 has achieved significant milestones since 2Q22 initiation DMC completed Cohort 1 (203 subjects) safety review and recommended study continuation without modification Cohort 1 immune responses1 were consistent with prior infant studies of HIL-214 Enrollment continues for remaining subjects T

  18. Slide 18: Development and regulatory strategy

    Development and regulatory strategy Initial clinical program focused on infant population Followed by immunobridging and/or efficacy studies in older adults Clinical program and concurrent epidemiology and pharmacoeconomic studies to support potential ACIP recommendations Phase 2b PoC study in infan

  19. Slide 19: Norovirus burden of disease compared with rotavirus and shingles

    Disease Age US cases US hospitalizations US deaths US economic burden (in 2020 dollars) Norovirus < 4 years 2.8 million 12,000 20 $1.2 billion 5 – 64 years 15.7 million 34,000 70 $6.4 billion > 65 years 3.7 million 50,000 1,250 $3.2 billion All ages 22 million 96,000 1,350 $10.6 billion Rotavirus (p

  20. Slide 20: Potential multi-billion dollar commercial opportunity

    Potential multi-billion dollar commercial opportunity Similar burden of disease between norovirus and rotavirus Two rotavirus vaccines were launched in 2006 and 2008 (RotaTeq and Rotarix) ACIP recommendation for routine infant use $1.5B global net sales in 2021 $210-360 per rotavirus vaccine course

  21. Slide 21: Anticipated milestones and capital position

    3Q22 1Q24 Phase 2b interim safety results first 200 subjects Anticipated milestones 4Q22 Phase 2b interim immunogenicity results first 200 subjects Phase 2b topline data Strong Capital position As of September 30, 2022: $292.1M cash $75M term loan: $5M drawn + up to $70M available prior to P2b topli

  22. Slide 22: Most advanced norovirus vaccine candidate

    Most advanced norovirus vaccine candidate Clinical PoC demonstrated in adults Phase IIb study ongoing in 3,000 infants Blockbuster potential commercial opportunity Highly experienced leadership team NASDAQ: HLVX*

HilleVax — Investor Presentation (January 2023) on 6ix